Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
The Clinical Respiratory Journal · 2024-12 · 18 (12)
DOI: 10.1111/crj.70037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 04.12.2024. Verfasst von Jin Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Key Program of Science and Technology of Traditional Chinese Medicine, Shandong Provincial Youth Program of Science and Technology of Traditional Chinese Medicine, Qingdao Medical and Health Research Program.
Abstract (Originalsprache)
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment choice for advanced non‐small cell lung cancer (NSCLC) patients with EGFR mutations. EGFR‐TKIs have made significant progress in the treatment of advanced NSCLC patients, but drug resistance issues still inevitably arise. The mechanism of drug resistance and subsequent treatment has been current research challenge and priority. Immune checkpoint inhibitors (ICIs) are a new choice for late‐stage NSCLC patients without druggable molecular alterations. Currently, several studies have applied ICIs therapy for NSCLC patients with EGFR‐TKIs resistance and explored the potential efficacy of ICIs. This review elaborates on the current status of immunotherapy after EGFR‐TKIs resistance, including ICIs monotherapy, combined with EGFR‐TKIs, chemotherapy, antiangiogenic drugs, and other therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China.
- The First Clinical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
ORCID-Profile: Jun Xiao
Förderung
- Shandong Provincial Key Program of Science and Technology of Traditional Chinese Medicine
- Shandong Provincial Youth Program of Science and Technology of Traditional Chinese Medicine
- Qingdao Medical and Health Research Program
- 2021 Special Fund for Clinical Research of Wu Jieping Medical Foundation
- 2022-2024 Qingdao Municipal Clinical Key Specialties-Climbing Peak Discipline Program
Zitieren
APA
Tian, J., Shi, Z., Zhao, L., Liu, P., Sun, X., Long, L., Zang, J., & Xiao, J. (2024). Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance. The Clinical Respiratory Journal, 18(12). https://doi.org/10.1111/crj.70037
Vancouver
Tian J, Shi Z, Zhao L, Liu P, Sun X, Long L, et al. Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance. The Clinical Respiratory Journal. 2024;18(12). doi:10.1111/crj.70037
BibTeX
@article{Tian2024,
author = {Tian, Jin and Shi, Zhiqi and Zhao, Lili and Liu, Peng and Sun, Xiaojun and Long, Lin and Zang, Jianhua and Xiao, Jun},
title = {Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance},
journal = {The Clinical Respiratory Journal},
year = {2024},
volume = {18},
number = {12},
doi = {10.1111/crj.70037}
}
EUVIMED